Overview

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

Status:
Unknown status

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.

Phase:

Phase 4

Details

Lead Sponsor:

Tennessee Retina

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept